NTHU
19.2.2020 10:02:05 CET | Business Wire | Press release
A research team led by Professor Hsueh-Shih (Sean) Chen of National Tsing Hua University has recently announced that they have developed a new quantum dot material which is more stable and provides more realistic color. The main limitations of the current quantum dot display materials is that they are unstable and easily damaged, and the team has rectified this by growing “shield” with approximately 1-nanometer at the crystal facets of each quantum dot. The new material has a wide range of applications, including the screens used in televisions, computers, mobile phones, and cameras.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200219005017/en/
With the support of NTHU, the team has already applied for patents for the new material and has established the HsinLight Inc. to produce it on a commercial scale. It is expected that the first quantum dot screens will begin production in 2020.
Most of the displays currently on the market are liquid crystal displays (LCD), which have a color gradation and saturation and can only display about one third of the colors visible to the human eye, and even the so-called “retinal grade” OLED displays used in such devices as iPhone 11 can only display about half of the colors visible to the human eye. Displays equipped with new QD material (QLED TV) will display nearly 90% of the colors visible to the human eye.
However, there are still a few challenges to be overcome before quantum dot material goes into widespread use. Chen explained that quantum dots are spherical crystals of about three nanometers in size, and are easily damaged by water and oxygeny molecules, which diminishes their luminosity. At present, major manufacturers such as Samsung control this problem by sandwiching the quantum dots in a layer of protective film, but it’s not cost-effective and easily lose the protective function if there is a small pin hole.
Inspired by the shield used by the comic book superhero Captain America in the Avengers series, Chen hit upon the idea of giving each quantum dot its own shields about one nanometer in size, which effectively resists water and oxidation and also increases material stability and the display’s lifespan.
In the past two years several companies have begun selling televisions with quantum dot technology, but due to the fragile nature of quantum materials, they are difficult to mass produce, and the price is relatively high. However, using Chen’s unique shield technology to protect the quantum dots will significantly reduce production costs.
A typical 55-inch quantum dot screen consists of more than 100 million trillion (10 to the 20th power) quantum crystals, and Chen's research team has developed a technique for precisely controlling the size of each quantum dot, so that each quantum crystal differs in size by no more than 0.5 nanometers. Precisely controlling the size of the quantum dots and shields allows them to accurately emit blue, green, yellow, orange, red, infrared, and other colors.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200219005017/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
